Patched-2 functions to limit Patched-1 deficient skin cancer growth
Autor: | Ilse Dingjan, Jan Paul Medema, Helene Damhofer, Cynthia Waasdorp, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, Allard C. van der Wal, Veronique L. Veenstra |
---|---|
Přispěvatelé: | CCA - Cancer biology and immunology, AGEM - Re-generation and cancer of the digestive system, Graduate School, Center of Experimental and Molecular Medicine, Pathology, ACS - Heart failure & arrhythmias, Oncology, Radiotherapy |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Patched Cancer Research Skin Neoplasms Cell Survival Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] Hedgehog signaling Patched-2 Receptor Mice 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center Cell Line Tumor Animals Humans Sonic hedgehog Hedgehog Tissue homeostasis Smoothened Original Paper biology Reverse Transcriptase Polymerase Chain Reaction Chemistry General Medicine Hedgehog signaling pathway Cell biology Patched-1 Receptor PTCH2 030104 developmental biology Oncology PTCH1 Carcinoma Basal Cell Basal cell carcinoma biology.protein Molecular Medicine Signal Transduction |
Zdroj: | Cellular Oncology (2011. Print), 41, 4, pp. 427-437 Cellular oncology, 41(4), 427-437. IOS Press Cellular Oncology (Dordrecht) Cellular Oncology (2011. Print), 41, 427-437 |
ISSN: | 2211-3436 2211-3428 |
DOI: | 10.1007/s13402-018-0381-9 |
Popis: | Purpose Basal cell carcinoma (BCC) is one of the most common skin cancers, and is typically driven by an aberrantly activated Hedgehog (Hh) pathway. The Hh pathway is regulated by interactions between the Patched-1 (Ptch1) and Smoothened (Smo) receptors. Smo is an activating receptor and is subject to inhibition by Ptch1. Following ligand binding to Ptch1, its inhibitory action is relieved and pathway activation occurs. This receptor interaction is pivotal to restraining uncontrolled cellular growth. Both receptors have been found to be frequently mutated in BCCs. Ptch2 is a Ptch1 paralog that exhibits overlapping functions in both normal development and tissue homeostasis. As yet, its contribution to cancer growth is poorly defined. Here we set out to assess how Ptch2 inhibits BCC growth. Methods We used several in vitro readouts for transcriptional and chemotactic Hh signaling in BCC-derived ASZ001 cells, and a novel xenograft model to assess in vivo BCC tumor growth. Gene editing by TALEN was used to untangle the different Ptch2-dependent responses to its ligand sonic hedgehog (Shh). Results We first defined the signaling competence of Ptch2 in Ptch1-deficient ASZ001 cells in vitro, and found that Ptch2 ligand binding drives their migration rather than eliciting a transcriptional response. We found that subsequent targeting of Ptch2 abrogated the chemotaxic effect. Next, we tested the contribution of Ptch2 to in vivo tumor growth using a xenograft model and found that reduced Ptch function results in increased tumor growth, but that selective pressure appatently acts against complete Ptch2 ablation. Conclusions We conclude that like Ptch1, Ptch2 exerts a tumor-suppressive function in BCC cells, and that after targeting of both paralogs, ligand-independent activation of the Hh pathway contributes to tumor growth. Electronic supplementary material The online version of this article (10.1007/s13402-018-0381-9) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |